Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
Recruiting now · Phase 1
Conditions studied: Non-Hodgkin's Lymphoma
In brief
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) CD19 and/or BCMA.
Key facts
- Study ID
- NCT07620314
- Run by
- Chinese PLA General Hospital
- People needed
- 9
- Starts
- 2026-07-16
- Expected to finish
- 2029-03-30
- Last updated by the study team
- 2026-07-20
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Biotherapeutic Department of Chinese PLA General Hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.